Inhibrx Biosciences, Inc. INBX

INBX reported Phase 2 HexAgon data: INBRX-106 plus Keytruda yielded 48.3% confirmed responses vs 26.5% for Keytruda alone in treatment-naïve, PD-L1-positive metastatic or unresectable recurrent head and neck cancer (63 evaluable). Complete responses were 13.8% vs 0%. Median progression-free survival 9.6 vs 4.9 months; six-month PFS 72.4% vs 42.8%. In HPV-positive subgroup (10 evaluable on combo, 9 on Keytruda), responses were 80% vs 33.3% with complete responses 30% vs 0%. Inhibrx plans to add about 50 HPV-positive patients to phase 2 to pursue an accelerated regulatory pathway; US HPV-positive head and neck cancer could be ~30,000 patients by 2029 with ~$1B in annual sales. Stock fell 8.8% after the release as management called the data de-risking and analysts remained positive. HPV-positive expansion and accelerated pathway could materially alter INBX's development and market potential.

Inhibrx Biosciences shares rose after positive Phase 2 data for head and neck cancer treatment. Positive Phase 2 head and neck cancer data drives Inhibrx share gains and enhances long-term prospects.

Inhibrx's INBRX-106 nearly doubled response rate and achieved interim median progression-free survival of 9.6 months in Phase 2 head and neck squamous cell carcinoma study. Positive Phase 2 data for INBRX-106 signals major advancement potential and valuation lift for the company.

Inhibrx Biosciences will host a webcast to deliver primary endpoint results from the INBRX-106 Phase 2 trial in first-line head and neck squamous cell carcinoma. Phase 2 data readout for INBRX-106 can materially shift INBX valuation, pipeline outlook, and investor sentiment.

Inhibrx Biosciences amended its loan agreement with Oxford Finance, expanding the total facility to $500.0 million. Expanded $500 million credit facility materially improves Inhibrx liquidity and runway for development programs.

Inhibrx Biosciences receives U.S. FDA acceptance of its BLA for Ozekibart in conventional chondrosarcoma patients. FDA BLA acceptance marks a major regulatory milestone that advances Ozekibart toward approval and can materially shift company trajectory.

Inhibrx Biosciences (INBX) announced positive interim results from the Phase 2 portion of the HexAgon study. Positive Phase 2 interim results validate clinical progress in INBX's pipeline, likely driving significant stock gains and advancing toward Phase 3.

Inhibrx Biosciences, Inc. (INBX) reported first quarter 2026 financial results, detailing revenue, expenses, cash position, and updates on clinical pipeline progress. Quarterly financial results influence stock performance through key metrics like cash runway and pipeline advancements in biotech.

Inhibrx Biosciences reports positive Phase 2 data for INBRX-106 in head and neck cancer, raising questions on whether INBX investors should act. Positive Phase 2 data for INBRX-106 in head and neck cancer marks a significant clinical milestone likely to boost INBX's pipeline value and stock performance.

Merck expands KEYTRUDA collaborations amid patent expiry pressures, partnering with Inhibrx Biosciences (INBX) to bolster its oncology portfolio. Merck's KEYTRUDA collaboration expansion with INBX provides significant strategic validation and potential revenue upside for INBX's development pipeline.

Inhibrx Biosciences (INBX) stock surges after positive results from a cancer trial. Positive cancer trial results represent a game-changing milestone that could fundamentally redefine INBX's oncology prospects and market trajectory.

Inhibrx Biosciences’ INBRX-106 combined with Keytruda outperformed Keytruda monotherapy in a Phase 2 cancer study. Phase 2 data showing INBRX-106 combo superior to Keytruda alone represents a major clinical advancement for INBX's oncology pipeline, likely boosting investor sentiment and stock performance.

Inhibrx Biosciences reported interim Phase 2 data for INBRX-106 in first-line head and neck squamous cell carcinoma (HNSCC), with initial results showing potential costimulatory benefits over PD-1 monotherapy. Interim Phase 2 data demonstrating INBRX-106's potential superiority over PD-1 monotherapy in first-line HNSCC signals a major pipeline advancement likely to enhance INBX's valuation and investor interest.

Inhibrx Biosciences, Inc. (INBX) will host a webcast presentation to provide a clinical update on the INBRX-106 HexaGon Study in first-line HNSCC. Clinical update presentation on INBRX-106 HexaGon Study in first-line HNSCC could significantly impact INBX's competitive positioning and investor sentiment.

Inhibrx Biosciences (INBX) valuation under review following promising Ozekibart clinical data and advancing regulatory momentum, highlighting potential upside for the biotech's pipeline and market position. Ozekibart data and regulatory momentum represent major pipeline advancements likely to significantly enhance INBX's valuation and investor sentiment.

Inhibrx Biosciences (INBX) shares surged 46.3% after releasing new positive data on Ozekibart for colorectal cancer and announcing plans for FDA interactions. Positive Ozekibart colorectal cancer data and FDA plans triggered a 46.3% stock surge, indicating major potential shifts in clinical progress and investor sentiment.

Inhibrx Biosciences reports 20% overall response rate for Ozekibart combination therapy in late-line colorectal cancer patients. 20% ORR for Ozekibart combo in late-line colorectal cancer indicates strong efficacy in unmet need, likely catalyzing partnerships, funding, and stock surge for INBX.

Inhibrx Biosciences (INBX) stock rose sharply after positive clinical update from colorectal cancer study. Upbeat clinical data from colorectal cancer study advances INBX pipeline and drives stock gains, signaling major positive shift in prospects.

Inhibrx Biosciences announced a clinical update on Ozekibart (INBRX-109), its bispecific antibody targeting PD-L1 and VEGF, showing encouraging antitumor activity and manageable safety in heavily pretreated late-line colorectal cancer patients, with plans for further development. Clinical data from Ozekibart in late-line colorectal cancer represents a major milestone for INBX's oncology pipeline, potentially boosting investor sentiment and market valuation.

Inhibrx Biosciences to host webcast presentation providing clinical update on Ozekibart (INBRX-109) in late-line colorectal cancer. Clinical update presentation on lead candidate Ozekibart in colorectal cancer signals potential major data readout that could significantly impact INBX's pipeline progress and stock performance.

Inhibrx Biosciences, Inc. (INBX) reported fourth quarter and fiscal year 2025 financial results. Financial results reporting influences key financial metrics and investor sentiment moderately.

Inhibrx Biosciences, Inc. is advancing its oncology programs, with plans for multiple data readouts expected in 2026. The company is focusing on its innovative therapies aimed at treating various cancers, which could enhance its position in the oncology market. These developments are part of Inhibrx's strategic efforts to drive growth and improve patient outcomes through targeted treatments. The upcoming data readouts and advancements in oncology programs are likely to significantly impact Inhibrx's market position and investor sentiment.

Inhibrx Biosciences, Inc. (INBX) has provided updates on its drug candidates INBRX-106 and Ozekibart, highlighting recent milestones that could influence the company's future. The updates suggest progress in clinical trials and potential market opportunities, prompting discussions about the company's valuation in light of these developments. Recent milestones in drug development are likely to significantly impact Inhibrx's market position and investor sentiment.

Inhibrx Biosciences, Inc. provided updates on its INBRX-106 program and the expansion cohorts of the ozekibart (INBRX-109) program. The company highlighted progress in clinical trials and ongoing research efforts aimed at advancing its therapeutic candidates. These updates are part of Inhibrx's strategy to enhance its pipeline and address unmet medical needs in oncology. Significant advancements in clinical programs could alter the company's trajectory and investor sentiment.

Inhibrx Biosciences, Inc. (INBX) reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue, expenses, and net loss. The company continues to advance its pipeline of therapeutic candidates, focusing on innovative treatments in oncology and autoimmune diseases. Management provided insights into ongoing clinical trials and strategic initiatives aimed at enhancing shareholder value. The financial performance reflects the company's commitment to research and development, despite challenges in the market. The financial results and ongoing clinical trials indicate a moderate influence on the company's future performance and market positioning.

Inhibrx Biosciences, Inc. (INBX) has received an upgraded growth outlook, reflecting improved expectations for its future performance. The company is focusing on advancing its pipeline and enhancing its market position, which has led to increased investor confidence. Analysts are optimistic about the potential for significant developments in the company's product offerings and overall strategy, suggesting a positive trajectory ahead. The improved growth outlook indicates significant potential for strategic advancements and market positioning.

Inhibrx Biosciences, Inc. (INBX) announced its participation in several upcoming scientific conferences, where it will present its latest research and developments in the field of biopharmaceuticals. These conferences provide a platform for the company to showcase its innovative therapies and engage with industry experts, potentially enhancing its visibility and collaboration opportunities. Participation in scientific conferences can moderately influence Inhibrx's visibility and networking opportunities, impacting future product development and market positioning.

Inhibrx Biosciences, Inc. (INBX) has reported breakthrough Phase 2 results for its drug Ozekibart, which shows promise in treating certain cancers. The positive outcomes from the trial could enhance the company's market position and attract investor interest. Analysts are now reevaluating the company's valuation in light of these results, suggesting a potential shift in future growth prospects and financial performance. The breakthrough Phase 2 results for Ozekibart are likely to significantly impact Inhibrx's market position and investor sentiment.

Inhibrx Biosciences, Inc. (INBX) experienced a significant stock surge following positive results from a Phase II clinical trial for its treatment targeting chondrosarcoma. The trial demonstrated promising efficacy, leading to increased investor confidence and market interest in the company's future prospects. This victory marks a crucial milestone for Inhibrx as it advances its product pipeline and strengthens its position in the oncology sector. The successful Phase II trial results are likely to significantly enhance Inhibrx's market position and investor sentiment.

Inhibrx Biosciences, Inc. (INBX) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company's operations or product pipeline. Increased trading activity suggests a moderate influence on market sentiment and potential interest in the company's future performance.